## Q2/FY2019 FINANCIAL RESULTS ENDED SEPTEMBER 30, 2019



Kenji Yasukawa, Ph.D. President and CEO Astellas Pharma Inc. October 31, 2019

# CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

2

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.





I

Q2/FY2019 Consolidated Financial Results and FY2019 Revised Forecasts



Initiatives for Sustainable Growth

Ш

**Capital Allocation** 



## Q2/FY2019 FINANCIAL RESULTS (CORE BASIS)


(billion yen)	Q2/FY18	Q2/FY19	Change	FY19 FCST *	Progress	CER growth
Revenue	647.1	650.5	+0.5%	1,224.0	53.1%	+3.4%
Cost of sales % of revenue	143.5 22.2%	138.9 21.3%	-3.3%			
SG&A expenses % of revenue	231.5 35.8%	226.1 34.8%	-2.4%			
R&D expenses % of revenue	99.6 15.4%	105.0 16.1%	+5.4%	211.0 17.2%	49.8%	
Amortisation of intangible assets	17.7	11.2	-36.6%			
Share of profit (loss) of investments accounted for using equity method	- 0.6	- 1.4	-			
Core operating profit	154.2	168.0	+8.9%	240.0	70.0%	+9.4%
Core profit	124.8	135.9	+8.9%	194.0	70.1%	
Core EPS (yen)	63.92	72.07	+12.8%	102.87	70.1%	
						Astellas

CER: Constant exchange rate

\* Announced in Apr 2019

## REVENUE ANALYSIS (YEAR ON YEAR)


Sales increase in XTANDI, XOSPATA, mirabegron and new products in Japan offset the LOE impacts of Vesicare and Tarceva, etc.



mirabegron (Betanis/Myrbetriq/BETMIGA) New products in Japan (Repatha, Suglat-Family, Linzess, Dafclir, BLINCYTO, EVENITY, Smyraf)

## CORE OP ANALYSIS (YEAR ON YEAR)

In addition to major products/new products contributing to an increase in gross profit, SG&A expenses decreased due to one-off factor resulting in 9% core OP increase



## Q2/FY2019 FINANCIAL RESULTS (FULL BASIS)

(billion yen)	Q2/FY18	Q2/FY19	Change	FY19 FCST *	Progress
Core operating profit	154.2	168.0	+8.9%	240.0	70.0%
Other income	4.7	7.2	+54.3%		
Other expense	32.0	13.0	-59.4%		
Operating profit	126.8	162.2	+27.9%	229.0	70.8%
Profit before tax	128.3	161.6	+25.9%	230.0	70.3%
Profit	103.9	128.5	+23.7%	182.0	70.6%
EPS (yen)	53.20	68.16	+28.1%	96.51	70.6%



\* Announced in Apr 2019

7

### SALES OF MAIN PRODUCTS: XTANDI, XOSPATA, MIRABEGRON

	Q2/FY18	Q2/FY19	(billion yen)
XTANDI	164.0	195.0 (+19%)	<ul> <li>Steady growth in all regions due to penetration in earlier stage of prostate cancer</li> <li>Increase of US M0 CRPC prescriptions</li> </ul>
XOSPATA* (Launched in Dec. 2018) * Total of JP, US		5.7	<ul> <li>In 2019 NCCN guideline, XOSPATA has been added as Category 1 for the treatment of FLT3 mut+ R/R AML patients. This category is for treatment with the highest level of evidence</li> <li>ADMIRAL study results published in New England Journal of Medicine</li> </ul>
mirabegron	68.6	78.8 (+15%)	<ul> <li>Double-digit growth in all regions</li> <li>Conducting disease awareness activities</li> <li>Increasing prescriptions as first choice therapy based on mechanism of action and product features</li> </ul>


mirabegron (Betanis/Myrbetriq/BETMIGA)

M0: Non-metastatic, CRPC: Castration-resistant prostate cancer, NCCN: National Comprehensive Cancer Network,

FLT3 mut+: FLT3 mutation positive, R/R: Relapsed or refractory, AML: Acute myeloid leukemia



Upward revision of initial forecasts (Global sales: 364.2 → 383.9 billion yen)




Established Markets: Europe, Canada, Australia

International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc. Greater China: China, Hong Kong, Taiwan

## NEW PRODUCTS IN JAPAN\*

Q2 sales increased significantly with continued launches/additional indications Upward revision of initial forecasts for new products (Appox.45.0  $\rightarrow$  60.0 billion yen)



\* New products in Japan (Repatha, Suglat-Family, Linzess, Dafclir, BLINCYTO, EVENITY, Smyraf)

## FY2019 REVISED FORECASTS: SUMMARY

- Steady performance of XTANDI and new products in Japan such as EVENITY
  - One-off factors that were not included into initial forecasts
    - ✓ Revenue
      - Transfer of three products in Asia region to Daiichi Sankyo
      - Upward revision of US Prograf (Increase in demand due to shortage of generic tacrolimus in the market)
    - ✓ Expenses
      - Reversal of loss allowance related to a domestic partner
- Factors affecting lower revenue in the second half that have been included into initial forecasts
  - LOE impact of Vesicare and Tarceva
  - > Termination of sale and distribution for Symbicort and KM bio products
  - NHI price revision in Oct. 2019 and lower sales prior to NHI price revision in Apr. 2020



## **REVISED FORECASTS FOR FY2019**

(billion yen)	FY19 Initial FCST	FY19 Revised FCST	Change
Revenue	1,224.0	1,256.0	+32.0
R&D expenses % of revenue	211.0	216.0	+5.0
Core operating profit	240.0	264.0	+24.0
Core profit	194.0	214.0	+20.0
Core EPS (yen)	102.87	113.49	+10.62
Operating profit	229.0	263.0	+34.0
Profit	182.0	210.0	+28.0
EPS (yen)	96.51	111.37	+14.86







Q2/FY2019 Consolidated Financial Results and FY2019 Revised Forecasts



Initiatives for Sustainable Growth



**Capital Allocation** 



## ENHANCEMENT OF INITIATIVES IN CHINA

Enhancement of development and regulatory functions for the development of late-stage projects Aiming for 200.0 billion yen sales in the overall Chinese business in late 2020s

Projects	indication	Current Status
	M1 CRPC	Regulatory decision expected in FY19
enzalutamide (XTANDI)	M0 CRPC	sNDA submitted in Oct 2019 based on global P3 study data
	M1 HSPC	FSFT of China P3 study in Sep 2019
gilteritinib (XOSPATA)	R/R AML	P3 study ongoing including China
enfortumab vedotin	mUC	Development plan under discussion
zolbetuximab	Gastric and GEJ adenocarcinoma	Will begin enrollment in China in global P3 studies in FY19
fezolinetant	MR-VMS	IND for P3 studies submitted
peficitinib	RA	Asian P3 study ongoing

### Progress of clinical development in China

astellas

M1: Metastatic, M0: Non-metastatic, CRPC: Castration-resistant prostate cancer, HSPC: Hormone-sensitive prostate cancer, sNDA: Supplemental new drug application, FSFT: First subject first treatment, R/R: Relapsed or refractory, AML: Acute myeloid leukemia, mUC: Metastatic urothelial cancer, GEJ: Gastroesophageal junction, MR-VMS: Menopause-related vasomotor symptoms, IND: Investigational new drug, RA: Rheumatoid arthritis

## CONTINUED PROGRESS ON 6 POST-POC PROJECTS

Development advancing as planned in Strategic Plan 2018

Progress since Q1/FY2019 announcement in July 2019

	Indication	<b>P1</b>	P2	P3	Filed	Approved
enzalutamide	M1 hormone-sensitive prostate cancer M0 hormone-sensitive prostate cancer				US,EU,JP	
gilteritinib	Relapsed or refractory AML Newly diagnosed AML: intensive chemo eligible Newly diagnosed AML: intensive chemo ineligible AML (Post-HSCT maintenance) AML (Post-chemo maintenance)					US, JP EU
enfortumab vedotin	mUC, platinum and PD-1/L1 inhibitor pretreated mUC, PD-1/L1 inhibitor pretreated mUC, 1st line				US	
zolbetuximab	Gastric and gastroesophageal junction adenocarcinoma Pancreatic adenocarcinoma					
roxadustat	Japan, anemia associated with CKD, on dialysis Japan, anemia associated with CKD, not on dialysis EU, anemia associated with CKD Chemotherapy-induced anemia					
fezolinetant	Menopause-related vasomotor symptoms					

M1: Metastatic, M0: Non-metastatic, AML: Acute myeloid leukemia, HSCT: Hematopoietic stem cell transplant, mUC: Metastatic urothelial cancer, CKD: Chronic kidney disease


### 6 POST-POC PROJECTS: STATUS UPDATE (Underlined: Updates since Q1/FY2019 announcement in July 2019)

#### enzalutamide gilteritinib enfortumab vedotin M1 HSPC **R/R FLT3 mut+ AML** mUC (platinum and • Filed in US (June 2019; PDUFA Date PD-1/L1 inhibitor pretreated) • JP: Label updated in Aug 2019 to set in Dec 2019 under Priority Review), include OS data • Filed in US in July 2019 EU (July 2019) and JP (July 2019) • EU: Approved in Oct 2019 (PDUFA Date set in Mar 2020 under M0 HSPC Priority Review) Phase 3 study: Ongoing Other AMLs mUC (1st line) China Phase 3 studies: Ongoing M1 CRPC: Regulatory decision · Results from Phase 1 study in expected in FY2019 combination with pembrolizumab • M0 CRPC: sNDA submitted in Oct 2019 presented at ESMO 2019 • M1 HSPC: Phase 3 study FSFT achieved in Sep 2019 zolbetuximab roxadustat fezolinetant Gastric and gastroesophageal Anemia associated with CKD **Menopause-related vasomotor** junction adenocarcinoma • EU: MAA targeting FY2019 symptoms · Phase 3 studies: Ongoing • JP: Approved for patients on dialvsis US/EU: Phase 3 studies FSFT in Sep 2019. For non-dialysis, TLR of achieved in Aug 2019 Pancreatic adenocarcinoma the remaining study expected in • JP: Development plan under Phase 2 study: Ongoing 2019 preparation China: IND for Phase 3 studies Chemotherapy-induced anemia submitted · Phase 2 study: FSFT achieved in Aug 2019

M1: Metastatic, M0: Non-metastatic, HSPC: Hormone-sensitive prostate cancer, CRPC: Castration-resistant prostate cancer, PDUFA: Prescription Drug User Fee Act, sNDA: Supplemental new drug application, FSFT: First subject first treatment, R/R: Relapsed or refractory, FLT3 mut+: FLT3 mutation positive, AML: Acute myeloid leukemia, OS: Overall survival, mUC: Metastatic urothelial cancer, ESMO: European Society for Medical Oncology, CKD: Chronic kidney disease, MAA: Marketing authorization application, TLR: Topline result, IND: Investigational new drug

## ENFORTUMAB VEDOTIN: mUC

Platinum and PD-1/L1 inhibitor pretreated: Filed in US in July 2019, PDUFA Date set in March 2020 under Priority Review
1st line: Results from Phase 1 EV-103 study in combination with pembrolizumab presented at ESMO 2019, Phase 3 program currently under preparation



### **SeattleGenetics**

mUC: Metastatic urothelial cancer, PDUFA: Prescription Drug User Fee Act, ESMO: European Society for Medical Oncology, Gem: Gemcitabine, Cis: Cisplatin, Carbo: Carboplatin

**A**astellas

### ENFORTUMAB VEDOTIN: EV-103 RESULTS (1/3) Objective Response Rate (ORR)

*High ORR (71%) in enfortumab vedotin + pembrolizumab cohorts in cisplatin-ineligible patients with locally advanced or metastatic UC* 

<b>ORR per RECIST v1.1 by investigator</b> 18 Jun 2019 data cut-off	<b>Patients (N=45)</b> n (%)		
Confirmed ORR 95% confidence interval	<b>32 (71)</b> (55.7, 83.6)		
Best Overall Response per RECIST v1.1			
Complete response	6 (13)		
Partial response	26 (58)		
Stable disease	10 (22)		
Progressive disease	1 (2)		
Not evaluable <sup>1</sup>	2 (4)		


1: Two patients did not have post-baseline response assessments before end-of-treatment; 1 withdrew consent and 1 died before any post-baseline response assessment

### **OSeattleGenetics**<sup>®</sup>

C. J. Hoimes, ESMO 2019 UC: Urothelial cancer, RECIST: Response evaluation criteria in solid tumors

### ENFORTUMAB VEDOTIN: EV-103 RESULTS (2/3) Maximum Percent Reduction from Baseline in Sum of Diameters of Target Lesions per Investigator

Activity regardless of PD-L1 expression





astellas

C. J. Hoimes, ESMO 2019 CPS: Combined positive score, CR: Complete response, PR: Partial response

### ENFORTUMAB VEDOTIN: EV-103 RESULTS (3/3) Treatment-Related Adverse Events (TRAE)

<b>TRAEs by preferred term</b> Any grade in≥ 20% of patients and	<b>Patients (N=45)</b> n (%)		
≥ Grade 3 in≥ 10% of patients	Any Grade	≥ Grade 3	
Overall	43 (96)	23 (51)	
Fatigue	22 (49)	4 (9)	
Alopecia	21 (47)	N/A	
Peripheral sensory neuropathy	21 (47)	2 (4)	
Diarrhea	18 (40)	2 (4)	
Decreased appetite	15 (33)	0	
Dysgeusia	14 (31)	N/A	
Nausea	13 (29)	0	
Pruritus	12 (27)	1 (2)	
Rash maculo-papular	12 (27)	3 (7)	
Weight decreased	10 (22)	0	
Anemia	9 (20)	2 (4)	
Lipase increased	7 (16)	6 (13)	

- 7 patients had treatment-related serious adverse events (16%)
- 4 treatment-related discontinuations of enfortumab vedotin + pembrolizumab due to adverse events (9%)
  - Peripheral sensory neuropathy most common: 2 patients
- 1 treatment-related death as reported by investigator (2%)
  - Multiple organ dysfunction syndrome
  - Confounded by concomitant acute onset of atrial fibrillation, corticosteroids, and amiodarone

N/A: Not applicable



C. J. Hoimes, ESMO 2019

**OSeattleGenetics**<sup>®</sup>

## ENFORTUMAB VEDOTIN:

Number of 1st Line Drug Treated Patients with Metastatic UC

*In addition to expanding the target patient number, expected to have longer duration of therapy in 1st line Potential sales size at peak including 1st line to be 100.0 - 200.0 billion yen* 

Urothelial Cancer (Annual)	All Stages (Incidence)	<b>Metastatic</b> (Incident + Newly Recurrent)	Drug Treated mUC (1L)	Drug Treated mUC (2L+*)
Total G7 (US/EU5/JP)	236,000	56,000	49,000	23,000
US	79,000	19,000	15,000	8,000
EU5	118,000	29,000	27,000	12,000
JP	39,000	8,000	7,000	3,000

Number of drug treated patients expected to rise after new drug launch



Kantar Health incident and newly recurrent patients mUC: Metastatic urothelial cancer


## ROXADUSTAT: DEVELOPMENT IN JAPAN



Approved in Japan in Sep 2019 for renal anemia in patients on dialysis as a first-in-class orally administered HIF-PH inhibitor

- Discovered by FibroGen and being developed by Astellas in Japan
- Novel mechanism of action, which is different from that of the current standard of care such as erythropoiesis-stimulating agents (ESAs)
- Orally administered, three times per week
- NDA approved for dialysis patients, based on the four Phase 3 studies in Japan, where roxadustat showed comparable efficacy (raising hemoglobin) to ESA and was well-tolerated

#### **Mechanism of action** Roxadustat activates a natural pathway to increase red blood cell production by inhibiting HIF-PH



• For non-dialysis, one Phase 3 study completed and another study TLR expected in 2019, followed by supplemental NDA submission



**A**astellas



HIF-PH: Hypoxia-inducible factor prolyl hydroxylase, NDA: New drug application, TLR: Topline result

### FOCUS AREA APPROACH: **IMMUNO-ONCOLOGY ASSETS**

Details of the immuno-oncology assets to be introduced at Astellas R&D Meeting on Dec 10, 2019

Immuno-oncology

			Current	t Stage	
Compound	Modality/Mechanism	Origin/Partner	Target Tumor	Preclinical /Research	Clinical Phase 1
ASP8374	Anti-TIGIT antibody	POTENZA *	(To be determined)		
ASP1948	Anti-NRP1 antibody	POTENZA *	(To be determined)		
ASP1951	GITR agonistic antibody	POTENZA *	(To be determined)		
ASP9801	Oncolytic virus	** <b>Solution</b> University	(To be determined)		
ASP7517	WT1 loaded artificial adjuvant vector cell (aAVC)		Acute myeloid leukemia, Myelodysplastic syndrome (as the first targets)		
(Not disclosed)	Other tumor antigens loaded aAVC		(Not disclosed yet)		

\* Acquired in 2018 (currently their programs classified into in-house ones), \*\* Programs developed under joint research



## PROGRESS IN FOCUS AREA APPROACH (1/2)

Licensing agreement with RIKEN for artificial adjuvant vector cell (aAVC) technology as a novel and promising immuno-oncology platform


aAVC characteristics

- Expects to show anti-tumor effects by activating both
  - ✓ "Innate immunity" through natural killer cells and
  - ✓ "Adaptive immunity" through antigen-specific cytotoxic T cells as well as long-term effects through long-lived memory T cells differentiated from cytotoxic T cells

#### Lead aAVC program - ASP7517

- aAVC loading WT1, a tumor antigen highly expressed in AML
- FSFT of Phase 1 part in Phase 1/2 study in AML and MDS achieved in Oct 2019

Natural




AML: Acute myeloid leukemia, FSFT: First subject first treatment, MDS: Myelodysplastic syndrome

## PROGRESS IN FOCUS AREA APPROACH (2/2)

Fast Track designated by FDA for ASP1128/MA-0217 program for patients at risk of acute kidney injury (AKI) after cardiac surgery

Mitochondria biology

- Mitochondrial dysfunction contributes to various disease pathogenesis
- Acquired Mitobridge that has expertise in mitochondrial biology-based R&D in 2018 and obtained their clinical and preclinical programs targeting mitochondrial functions for kidney, muscle and other kind of diseases
- "Mitochondria biology" is one of our four "Primary Focus"



#### **Unmet medical needs of AKI**

- AKI is rapid loss of renal function and associated with progression to chronic kidney disease and end-stage renal disease<sup>1</sup> and increased morbidity/mortality<sup>2,3</sup>
- AKI occurs in up to 30% of cardiac surgery patients<sup>4</sup>, and 2% to 6% of these cases require dialysis<sup>2,5,6</sup>
- No approved therapies available for either preventing or treating AKI

#### ASP1128/MA-0217 characteristics

- Selective PPARδ modulator, discovered by Mitobridge
- Designated by FDA as a Fast Track development program for patients who are at increased risk of developing moderate to severe AKI after coronary artery bypass graft and/or valve surgery
- Phase 2a study ongoing



1: Molitoris BA, 2014, 2: Hu J, *et al.*, 2016, 3: Bellomo R, *et al.*, 2012, 4 : Rosner MH & Okusa MD, 2006, 5: Thiele RH, *et al.*, 2015, 6: Bastin AJ, *et al.*, 2013 FDA: Food and Drug Administration, PPARδ: peroxisome proliferator-activated receptor delta

Mitochondria

## **KEY EVENTS EXPECTED IN FY2019**

Regulatory decisions	enzalutamide	M1 castration-resistant prostate cancer (China) M1 hormone-sensitive prostate cancer (US <sup>a</sup> )
	enfortumab vedotin	Metastatic urothelial cancer, platinum and PD-1/L1 inhibitor pretreated (US <sup>a,b</sup> )
Regulatory submissions *	roxadustat	Anemia associated with chronic kidney disease, dialysis/non-dialysis (EU)
Data readouts	roxadustat	P3 study in Japanese patients (anemia associated with chronic kidney disease, non-dialysis: 1517-CL-0310)

\* Subject to study outcome, internal assessment, decision and regulatory consultation, as appropriate a: Priority Review granted, b: Breakthrough Therapy designated


Please refer to R&D pipeline list for details including target disease



## UPDATES IN Rx+<sup>TM</sup> PROGRAM


- New digital healthcare solutions using gamification-

- "Health Mock Lab.", a virtual framework for industry-academia collaboration with Yokohama City University and Tokyo University of the Arts, has launched.
- Aiming to create and commercialize new digital healthcare solutions using gamification.



## UPDATES IN Rx+<sup>TM</sup> PROGRAM

- Novel ultra-small implantable medical devices-
- Joint research and development agreement with iota Biosciences, Inc.
- Expecting to develop new bio sensing and treatment measures using ultra-small implantable medical devices.
- Iota and Astellas will jointly design detailed specifications of implantable medical devices and conduct preclinical studies for several diseases with high unmet medical needs.
   Programming



Dust Data Transfer

Seo D et al., Neuron, 2016

iota's proprietary technology-

- $\checkmark$  Uses ultrasound as a tool for power supply and wireless communication
- ✓ Ability to develop battery-free and wireless ultra-small implantable medical devices.
- $\checkmark$  This platform enables monitor and stimulate organs directly.





## AGENDA

I

Q2/FY2019 Consolidated Financial Results and FY2019 Revised Forecasts



Initiatives for Sustainable Growth


Ш

**Capital Allocation** 



## CAPITAL ALLOCATION

Top priority is investment for strategic business growth Dividends to be increased continuously based on mid-and long-term growth Share buybacks to be implemented in a flexible manner





# R&D meeting - Approaches to immuno-oncology -

Date: December 10, 2019



# APPENDIX

## Q2/FY2019: REVENUE BY REGION

(billion yen)	Q2/FY18	Q2/FY19	Change
Japan	180.7	183.3	+1.5%
United States	207.9	216.7	+4.2%
Established Markets	149.6	146.7	-1.9%
Greater China	29.3	29.4	+0.4%
International	63.2	63.4	+0.3%
Established Markets: Europe, Canada, Austral	ia		

Greater China: China, Hong Kong, Taiwan International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.



## Q2/FY2019: SALES OF MAIN PRODUCTS

(billion yen)	Q2/FY18	Q2/FY19	Change	CER growth	FY19 FCST*	Progress
XTANDI	164.0	195.0	+18.9%	+22.8%	364.2	53.5%
XOSPATA	-	5.7	-	-	15.1	37.7%
OAB products	116.7	103.8	-11.0%	-8.8%	202.4	51.3%
mirabegron	68.6	78.8	+14.9%	+17.5%	160.6	49.1%
Vesicare	48.1	25.1	-47.9%	-46.2%	41.8	60.0%
Prograf	100.4	96.2	-4.2%	-0.0%	187.7	51.2%
						Astell

Prograf: Incl. Advagraf/Graceptor/ASTAGRAF XL

OAB products: Vesicare+mirabegron (Product name: Betanis/Myrbetriq/BETMIGA)

\*Announced in Apr. 2019

## FX RATE (ACTUAL)

### Average rate for the period

Currency	Q2/FY18	Q2/FY19	change
USD	110 yen	109 yen	-2 yen
EUR	130 yen	121 yen	-8 yen

### Change in closing rate from PY end

Currency	Q2/FY18	Q2/FY19
USD	+7 yen	-3 yen
EUR	+2 yen	-7 yen

Fx impact on elimination of unrealized gain: COGs ratio -1.4ppt



## FY2019 REVISED FCST: FX RATE & FX SENSITIVITY

Exchange rate (yen) Average for the period	FY19 Initial FCST	FY19 Revised FCST
USD	110 yen	108 yen
EUR	125 yen	120 yen

FX impacts vs. initial forecasts (billion yen)

- Revenue : -27.9
- Core operating profit: -7.0

Forecast rates from Q3/FY2019 onwards: 108 USD/yen, 118 EUR/yen

#### Estimated Fx sensitivity (Q3 and onward) of FY2019 revised forecasts by 1 yen appreciation\*

Currency	Averag 1 yen higher tha	Year-end rate 1 yen higher than assumption	
	Revenue	Core OP	Core OP
USD	Approx2.6 bil yen	Approx0.6 bil yen	Approx. +0.3 bil yen
EUR	Approx1.4 bil yen	Approx0.6 bil yen	Approx. +0.2 bil yen



\*Sensitivity to fluctuation of Fx rates used for consolidation of overseas affiliates' results compared to forecasted rates from Q3/FY2019 and onwards


## BALANCE SHEET/CASH FLOW HIGHLIGHTS

(billion yen)	FY18 end	Sep. 2019
Total assets	1,897.6	1,979.8
Cash and cash equivalents	311.1	311.4
Total equity attributable to owners of the parent Equity ratio (%)	1,258.4 66.3%	1,296.1 65.5%

(billion yen)	Q2/FY18	Q2/FY19	FY18
Cash flows from operating activities	112.1	101.7	258.6
Cash flows from investing activities	-7.8	-46.6	-41.8
Free cash flows	104.3	55.1	216.9
Cash flows from financing activities	-136.5	-46.0	-233.7
Acquisition of treasury shares	-100.4	-1.2	-160.4
Dividends paid	-35.6	-35.8	-72.1



### DETAILS OF SHAREHOLDER RETURNS






\* The Company conducted a stock split of common stock at a ratio of 5 for 1 with an effective date of April 1, 2014, Figures are calculated based on the number of shares issued after the stock split (excluding treasury shares) on the assumption that the stock split was conducted at the beginning of fiscal year 2005.

\*\*From fiscal year 2013, figures are in accordance with International Financial Reporting Standards (IFRS)

#### FILING OPPORTUNITIES ANNOUNCED IN STRATEGIC PLAN



M0: Non-metastatic, M1: Metastatic, CPRC: Castration-resistant prostate cancer, HSPC: Hormone-sensitive prostate cancer, R/R: Relapsed or refractory, AML: Acute myeloid leukemia, CKD: Chronic kidney disease, HSCT: hematopoietic stem cell transplantation, MR-VMS: menopause related vasomotor symptoms

# ROBUST PIPELINE OF ASTELLAS

Phase 1	Phase 2	Phase 3	Filed			
ASP1235/AGS62P1	zolbetuximab (Pancreatic adenocarcinoma)	enzalutamide (M0 HSPC, M1 HSPC: China)	enzalutamide (M1 CRPC: China)			
ASP8374/PTZ-201	ASP1650 (Testicular cancer)	gilteritinib (R/R AML: China, Other AML)	enzalutamide (M1 HSPC: US,EU,JP)			
ASP1948/PTZ-329	reldesemtiv (SMA, ALS)	enfortumab vedotin (Urothelial cancer)	enzalutamide			
ASP1951/PTZ-522	ASP7317 (Dry AMD, etc.)	zolbetuximab	(M0 CRPC: China)			
	ASP1128/MA-0217 (AKI)	(Gastric and GEJ adenocarcinoma)	enfortumab vedotin (Metastatic urothelial cancer, platinum			
ASP9801	ASP3772 (Pneumococcal disease)	peficitinib	and PD-1/L1 pretreated: US)			
ASP7517	FX-322 (Sensorineural hearing loss)					
ASP0892	bleselumab <sup>(rFSGS)</sup>	roxadustat	fidaxomicin			
ASP0367/MA-0211	ASP8302 (Underactive bladder)	(Anemia associated with CKD, EU: Non-dialysis/dialysis,	( <i>Clostridium difficile</i> infection in pediatric patients: EU)			
MucoRice-CTB	roxadustat <sup>(CIA)</sup>	JP: Non-dialysis)	micafungin (Invasive candidiasis in neonates and young infants: US)			
	ASP0819 (Fibromyalgia)	fezolinetant (MR-VMS)				
ASP8062	ASP4345 (CIAS)		* Received Complete Response Letter			
ASP1617	isavuconazole (Pediatric, US)		from FDA in Aug 2017			
Oncology 📕 Projects with Focus Area approach (excluding Immuno-oncology projects) 📕 Others						


Please refer to R&D pipeline list for details including target disease.

**X**astellas

SMA: Spinal muscular atrophy, ALS: Amyotrophic lateral sclerosis, AMD: Age-related macular degeneration, AKI: Acute kidney injury, rFSGS: Recurrence of focal segmental glomerulosclerosis, CIA: Chemotherapy-induced anemia, CIAS: Cognitive impairment associated with schizophrenia, M0: Non-metastatic, M1: Metastatic, HSPC: Hormone-sensitive prostate cancer, CRPC: Castration-resistant prostate cancer, R/R: Relapsed or refractory, AML: Acute myeloid leukemia, GEJ: Gastroesophageal junction, OAB: Overactive bladder, NDO: Neurogenic detrusor overactivity, CKD: Chronic kidney disease, MR-VMS: Menopause-related vasomotor symptoms, FDA: Food and Drug Administration

### PROGRESS IN OVERALL PIPELINE

Phase 1 entry to approval, since 1Q/2019 financial results announcement in July 2019






AGS-16C3F: Renal cell carcinoma (Phase 2) ASP6294: Bladder pain syndrome / interstitial cystitis (Phase 2)

Note: Phase 1 entry is defined as confirmation of IND open. Phase transition is defined by approval of company decision body for entering to next clinical phase. Filing is defined as submission of application to health authorities. Discontinuation is defined by the decision of company decision body.



IND: Investigational new drug

# ENZALUTAMIDE: ANDROGEN RECEPTOR INHIBITOR



- M0 CRPC: sNDA submitted in Oct 2019, based on global Phase 3 PROSPER study data
  - M1 HSPC: FSFT of Phase 3 China-ARCHES study in Sep 2019

astellas

42


Underlined: Updates since Q1/FY2019 announcement in July 2019

hzei

M1: Metastatic, M0: Non-metastatic, HSPC: Hormone-sensitive prostate cancer, CRPC: Castration-resistant prostate cancer,

ADT: Androgen deprivation therapy, PDUFA: Prescription Drug User Fee Act, sNDA: Supplemental new drug application, FSFT: First subject first treatment

# GILTERITINIB: FLT3 INHIBITOR




<u>Underlined</u>: Updates since Q1/FY2019 announcement in July 2019 FLT3 mut+: FLT3 mutation positive, AML: Acute myeloid leukemia, OS: Overall survival, FSFT: First subject first treatment, HSCT: Hematopoietic stem cell transplant, BMT-CTN: Blood and Marrow Transplant - Clinical Trial Network

#### 43

# **ENFORTUMAB VEDOTIN: NECTION-4 TARGETED ADC**

mUC Treatment Landscape Overall treatment flow similar among regions, although standard of care and approved drugs can vary

44




#### **OSeattleGenetics**<sup>®</sup>

Underlined: Updates since Q1/FY2019 announcement in July 2019

ADC: Antibody-drug conjugate, mUC: Metastatic urothelial cancer, Gem: Gemcitabine, Cis: Cisplatin, Carbo: Carboplatin, FSFT: First subject first treatment, PDUFA: Prescription Drug User Fee Act. ESMO: European Society for Medical Oncology. NSCLC: Non-small cell lung cancer

## ENFORTUMAB VEDOTIN: EV-103 STUDY DESIGN





**OSeattleGenetics** C. J. Hoimes, ESMO 2019

EV: enfortumab vedotin, pembro: pembrolizumab, 1L: 1st line, 2L: 2nd line, cis: cisplatin, carbo: carboplatin, ESMO: European Society for Medical Oncology

astellas

#### ZOLBETUXIMAB: ANTI-CLAUDIN 18.2 MONOCLONAL ANTIBODY

#### Target: Claudin 18.2

- Claudin is a major structural component of tight junctions and seals intercellular space in epithelial sheets
- Broadly expressed in various cancer types
  - ~70% of gastric tumors; ~30% of these meet the eligibility criteria for the ongoing Phase 3 studies
  - ~60% of primary pancreatic adenocarcinomas; approx. 20% of these meet the eligibility criteria for the ongoing Phase 2 study

# Gastric and gastroesophageal junction (GEJ) adenocarcinoma

- Target patient population: locally advanced and metastatic gastric and GEJ adenocarcinoma with high Claudin 18.2 expression
- Gastric cancer is the third leading cause of cancer death worldwide <sup>1</sup>
- Overall 5-year survival rate for metastatic gastric and GEJ cancer is under 20% <sup>2,3</sup>
- Median overall survival for Stage IV gastric cancer is 10-15 months <sup>4,5</sup>


	Gastric and GEJ adenocarcinoma	P3: SPOTLIGHT	Combo with mFOLFOX6, vs. placebo	n=550	FSFT: Oct 2018
		P3: GLOW	Combo with CAPOX, vs. placebo	n=500	FSFT: Jan 2019
		P2: ILUSTRO	Monotherapy, Combo with mFOLFOX6	n=102	FSFT: Sep 2018
	Pancreatic adenocarcinoma	P2	Combo with nab-paclitaxel and gemcitabine, vs. placebo	n=141	FSFT: May 2019



1: WHO Cancer Fact Sheet - Globocan 2018, 2: Pennathur A, *et al.*, 2013, 3: Sahin U, *et al.*, 2008, 4: 2017 RDPAC survey, 5: lizumi S, *et al.* 2018 mFOLFOX6: 5-FU, leucovorin and oxaliplatin, CAPOX: Capecitabine and oxaliplatin, FSFT: First subject first treatment

# FEZOLINETANT: NK3 RECEPTOR ANTAGONIST

US/EU Phase 3 studies: FSFT of all the 3 studies in Aug 2019



\* A minimum average of 7 to 8 moderate to severe VMS per day, or 50 to 60 per week Moderate hot flush is associated with sensation of heat with sweating, and severe hot flush causes cessation of activity



<u>Underlined</u>: Updates since Q1/FY2019 announcement in July 2019 FSFT: First subject first treatment, VMS: Vasomotor symptoms, DBT: Double-blind trial, QD: Once daily

# ON THE FOREFRONT OF HEALTHCARE CHANGE

